China State FDA Issues Warning In Wake Of Heparin Safety Concerns
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - In the wake of a U.S. safety scare related to Baxter Healthcare's heparin, China's State FDA has warned foreign pharmaceutical companies to conduct business with only licensed Chinese companies
You may also be interested in...
China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference
SHANGHAI - China's State FDA is planning to launch a drug master file system to establish better controls for active pharmaceutical ingredients and drug excipients
China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference
SHANGHAI - China's State FDA is planning to launch a drug master file system to establish better controls for active pharmaceutical ingredients and drug excipients
China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference
China’s State FDA plans to launch a drug master file system and may integrate that system into existing regulations.